{"id":553846,"date":"2021-07-21T17:46:01","date_gmt":"2021-07-21T17:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553846"},"modified":"2021-07-21T17:46:01","modified_gmt":"2021-07-21T17:46:01","slug":"hedgehog-pathway-inhibitors-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hedgehog-pathway-inhibitors-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553846.html","title":{"rendered":"Hedgehog Pathway Inhibitors Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1626785883.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hedgehog Pathway Inhibitors Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1626785883.jpeg\" alt=\"Hedgehog Pathway Inhibitors Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cHedgehog Pathway Inhibitors Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Hedgehog Pathway Inhibitors pipeline landscapes. It comprises Hedgehog Pathway Inhibitors pipeline drug profiles, including clinical and non-clinical stage products.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hedgehog-pathway-inhibitors-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Hedgehog Pathway Inhibitors Pipeline Insight<\/strong>&rdquo;<\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Hedgehog Pathway Inhibitors pipeline landscapes. It comprises Hedgehog Pathway Inhibitors pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hedgehog Pathway Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hedgehog Pathway Inhibitors pipeline products.&nbsp; &nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d3bb2001f35af60d3903ff4f27dc6cf6.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hedgehog-pathway-inhibitors-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hedgehog Pathway Inhibitors Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as<\/span><span> Nelum Pharmaceuticals, PellePharm, Mayne Pharma, Impact Therapeutics, <\/span><span>etc., are developing therapies for the treatment of Hedgehog Pathway Inhibitors.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Emerging therapies such as <\/span><span>NLM-001, Patigetib, SUBA-itraconazole, IMP5471, <\/span><span>are expected to have a significant impact on the <\/span><span>&nbsp;Hedgehog Pathway Inhibitors <\/span><span>market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The Hedgehog Pathway Inhibitors market size shall increase during the forecast period (2018&ndash;2030) due to the launch of upcoming therapies.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The US accounted for XX% of the Hedgehog Pathway Inhibitors market size in 2018.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hedgehog-pathway-inhibitors-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hedgehog Pathway Inhibitors Clinical Trials Analysis &nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Hedgehog pathway inhibitors are small molecules that inhibit the activity of a component of the Hedgehog signalling pathway. Due to the role of aberrant Hedgehog signalling in tumour progression and cancer stem cell maintenance across cancer types, inhibition of the Hedgehog signalling pathway is usually a useful strategy for restricting tumour growth and for preventing the recurrence of the disease post-surgery or post-chemotherapy.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hedgehog Pathway Inhibitors Emerging Drugs<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>NLM-001 by Nelum Pharmaceuticals&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Patigetib by PellePharm<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SUBA-itraconazole by Mayne Pharma<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>IMP5471 by Impact Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>And others.<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Scope of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hedgehog-pathway-inhibitors-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hedgehog Pathway Inhibitors Pipeline Drug Insight<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Coverage: <\/span><span>Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major Players:<\/span><span> Nelum Pharmaceuticals, PellePharm, Mayne Pharma, Impact Therapeutics, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline Therapies: <\/span><span>NLM-001, Patigetib, SUBA-itraconazole, IMP5471, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Hedgehog Pathway Inhibitors Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\"><strong><span id=\"docs-internal-guid-82b65847-7fff-c368-8e55-3c7c7c67490e\">Get a customized pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hedgehog-pathway-inhibitors-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Hedgehog Pathway Inhibitors Drugs Pipeline Report<\/a><\/span><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hedgehog-pathway-inhibitors-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hedgehog-pathway-inhibitors-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cHedgehog Pathway Inhibitors Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Hedgehog Pathway Inhibitors pipeline landscapes. It comprises Hedgehog Pathway Inhibitors pipeline drug profiles, including clinical and non-clinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hedgehog-pathway-inhibitors-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553846.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-553846","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553846"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553846\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}